Hormone Therapy’s Boxed Warning Is Being Rewritten: What Changed for Women in Menopause, and What Didn’t

For more than two decades, the box on a menopause hormone prescription carried a stark message: risks of heart disease, breast cancer and probable dementia. That box is now being rewritten, one product at a time. On Oct. 30, the Food and Drug Administration approved new labels for three more estradiol patches, bringing to nine the menopausal hormone therapy products whose boxed warnings no longer carry those statements, according to FDA’s list of updated labels. (HNC reported the news Oct. 31.)

The change matters to a lot of people. About 41 million U.S. women were ages 45 to 64 in 2020, but only about 2 million women ages 46 to 65 received a prescription for systemic hormone therapy that year, FDA said. Here is what changed, what did not, and what to ask.

Why did hormone therapy get a boxed warning in the first place?

The warnings trace to the Women’s Health Initiative (WHI), two large trials that began in the 1990s. One tested estrogen plus progestin in women with a uterus; the other tested estrogen alone in women without one. Both were stopped early, in 2002 and 2004, after investigators reported a higher risk of breast cancer in the combined-therapy trial and a higher risk of stroke in the estrogen-alone trial, according to FDA. Related WHI studies in women 65 to 79 also reported a higher risk of probable dementia.

Starting in 2003, FDA approved class-wide label changes that eventually included a boxed warning, the agency’s most prominent safety alert, covering cardiovascular disorders, invasive breast cancer and probable dementia.

What made FDA change course?

The core argument is about age. The average WHI participant was 63, FDA noted, while women typically have bothersome hot flashes and night sweats much earlier, and the average age of menopause in the U.S. is 51. The dementia findings came from women 65 to 79, a group much older than most women who start therapy.

After reviewing later analyses and long-term WHI follow-up, holding an expert panel in July 2025 and asking for public input, FDA asked manufacturers in November 2025 to revise their labels. In February 2026, it approved the first six. The agency said randomized studies show women who start hormone therapy within 10 years of menopause, generally before 60, have lower all-cause mortality and fewer fractures.

What exactly changed on the label, and what stayed?

FDA’s requested changes for all hormone therapy products, including vaginal estrogen, were to:

• Remove cardiovascular disease, breast cancer and probable dementia language from the boxed warning.
• Remove the boxed warning on endometrial cancer, except for systemic estrogen-alone products.
• Drop the boxed recommendation to use the lowest effective dose for the shortest time.
• Remove the probable dementia warning from the label altogether.

Just as important is what remains. Systemic products keep their cardiovascular and breast cancer warnings in the body of the label, and systemic estrogen-alone products keep a boxed warning about endometrial cancer. Systemic labels also add guidance on considering therapy for moderate to severe hot flashes in women under 60 or within 10 years of menopause.

Do menopause experts agree?

Partly. When FDA announced the plan in November 2025, The Menopause Society said it agreed with removing the boxed warning on low-dose vaginal estrogen, which it called “a safe and effective therapy” for a condition that affects most menopausal women. But the society added that “systemic estrogen still comes with potential risks in certain individuals that should be reviewed in detail with women initiating therapy.”

The society said risks are low for younger, healthy women who start close to menopause and greater for women who start later. In other words, a shorter warning box does not mean hormone therapy is right for everyone.

Why are some women having trouble finding patches?

Demand rose after the November 2025 announcement, FDA said in a September update, and some patients have had trouble finding their usual patch. In its Oct. 30 announcement, HHS said it was not aware of an imminent risk of a nationwide shortage and that output from the six makers of approved estradiol patches had doubled over the past 12 months. Availability still varies by brand, strength and location.

FDA advises patients who cannot find their patch to ask their pharmacist about an equivalent product, ask their provider about alternatives such as gels or creams, and not stop or change medication on their own.

What should women ask their doctor now?

• Am I within 10 years of menopause, or under 60, and how does my age change the balance of benefits and risks?
• Does my personal or family history of breast cancer, blood clots, stroke or heart disease affect my options?
• Would vaginal estrogen alone treat my symptoms, or do I need systemic therapy?
• If I have a uterus, do I need a progestogen along with estrogen?

Key Takeaways

• Nine menopausal hormone therapy products now have labels without boxed warnings on heart disease, breast cancer and probable dementia, per FDA’s Oct. 30 list.
• The warnings came from WHI trials stopped in 2002 and 2004; FDA now says those participants were older than most women starting therapy.
• Cardiovascular and breast cancer warnings remain in the body of systemic product labels, and estrogen-alone products keep a boxed endometrial cancer warning.
• The Menopause Society backed the change for low-dose vaginal estrogen but says systemic therapy still carries risks for some women.
• HHS says it sees no imminent nationwide shortage, though patch availability varies.

Frequently Asked Questions

Featured image: Generic once-weekly estradiol transdermal patches. Illustrative photo. (Photo by Medgirl131, CC BY-SA 4.0, via Wikimedia Commons)